Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$142.13 USD

142.13
427,972

+1.70 (1.21%)

Updated Sep 22, 2025 04:00 PM ET

After-Market: $141.17 -0.96 (-0.68%) 4:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.

    Zacks Equity Research

    IDEXX Gains Ground on Solid CAG Business Amid Forex Woes

    by Zacks Equity Research

    IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.

      Zacks Equity Research

      Here's Why You Should Hold On to Quest Diagnostics (DGX) Now

      by Zacks Equity Research

      Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.

        Zacks Equity Research

        Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout

        by Zacks Equity Research

        Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.

          Zacks Equity Research

          Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit

          by Zacks Equity Research

          Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.

            Zacks Equity Research

            Genomic Health Prostate Cancer Business Solid, Cost Woes Stay

            by Zacks Equity Research

            Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.

              Zacks Equity Research

              Here's Why You Should Invest in athenahealth (ATHN) Now

              by Zacks Equity Research

              Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.

                Zacks Equity Research

                Varian's (VAR) ProBeam System Gets Picked by Delray Medical

                by Zacks Equity Research

                Varian Medical's (VAR) coveted ProBeam platform sees a slew of developments; market prospects solid.

                  Zacks Equity Research

                  Here's Why You Should Hold on to Abiomed (ABMD) for Now

                  by Zacks Equity Research

                  Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.

                    Zacks Equity Research

                    Amedisys Ties Up With Medalogix to Boost Home Health Unit

                    by Zacks Equity Research

                    Amedisys (AMED) pursues deals to boost Home Health business.

                      Zacks Equity Research

                      Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

                      by Zacks Equity Research

                      Strong fundamentals and a solid Q2 aid Veeva (VEEV).

                        Zacks Equity Research

                        Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

                        by Zacks Equity Research

                        Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

                          Zacks Equity Research

                          Here's Why You Should Invest in Phibro (PAHC) Right Now

                          by Zacks Equity Research

                          Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.

                            Zacks Equity Research

                            Here's Why You Should Buy Inogen (INGN) Stock Right Now

                            by Zacks Equity Research

                            Inogen (INGN) gains from strong Q2 results and bright global prospects.

                              Zacks Equity Research

                              Here's Why You Should Invest in Genomic Health (GHDX) Now

                              by Zacks Equity Research

                              Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.

                                Zacks Equity Research

                                Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit

                                by Zacks Equity Research

                                Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.

                                  Zacks Equity Research

                                  New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

                                  by Zacks Equity Research

                                  Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

                                    Zacks Equity Research

                                    Wright Medical Buys Cartiva to Boost Lower Extremities Unit

                                    by Zacks Equity Research

                                    Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

                                      Zacks Equity Research

                                      STERIS (STE) Strategic Growth Strong, Competition a Woe

                                      by Zacks Equity Research

                                      STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

                                        Zacks Equity Research

                                        Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

                                        by Zacks Equity Research

                                        Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                                          Zacks Equity Research

                                          Omnicell Patient Engagement Unit to Aid Medication Adherence

                                          by Zacks Equity Research

                                          Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                                            Sweta Jaiswal headshot

                                            Tap the Sleep Apnea Devices Market Boom With These 3 Stocks

                                            by Sweta Jaiswal

                                            Consider these three stocks in the sleep apnea devices market for grand returns.

                                              Zacks Equity Research

                                              Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                                              by Zacks Equity Research

                                              Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

                                                Zacks Equity Research

                                                Here's Why You Should Invest in Illumina (ILMN) Stock Now

                                                by Zacks Equity Research

                                                Illumina (ILMN) gains on strategic partnerships and international prospects.

                                                  Zacks Equity Research

                                                  Ecolab's New Aquanomic Enhances Laundry Operations at Hotels

                                                  by Zacks Equity Research

                                                  Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.